123 Main Street, New York, NY 10001
The U.S. National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) Tech program has awarded Co-Dx™ $1.2 million to complete the development of its upper respiratory panel.
The multiplex test for influenza A/B, COVID-19, and respiratory syncytial virus runs on the firm’s Co-Dx PCR Home™ Testing Platform. Co-Dx will use the RADx funding to finish the assay’s development and prepare for clinical trials.
Read the article here:
Co-Diagnostics, Inc.
2401 S. Foothill Dr. Suite D
Salt Lake City, UT 84109 USA
1 (801) 438-1036
info@co-dx.com
Co-Dx, Co-Primers, Logix Smart, Co-Dx Box, PCR Home, PCR Pro, and Vector Smart, and unless otherwise specified, all other product and service names appearing in this Internet site are trademarks owned by Co-Diagnostics, Inc., its subsidiaries or affiliates. No use of any Co-Diagnostic trademark, trade name, or trade dress in this site may be made without the prior written authorization of Co-Diagnostics, except to identify the product or services of the company.
TaqMan is a trademark of Roche Molecular Systems.